ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2013
The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- From bench to bedside: the evolution and future of prostate-specific antigen testing.Medical oncology (Northwood, London, England) · 2025Review
- Integrating machine learning driven virtual screening and molecular dynamics simulations to identify potential inhibitors targeting PARP1 against prostate cancer.Scientific reports · 2025Article
- Age limit for familial prostate cancer screening.Caspian journal of internal medicine · 2025Article
- Bimodal MRI/Fluorescence Nanoparticle Imaging Contrast Agent Targeting Prostate Cancer.Nanomaterials (Basel, Switzerland) · 2024Article
- Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era.Scientific reports · 2024Article
- Ultrasound-guided transperineal vs transrectal prostate biopsy: A meta-analysis of diagnostic accuracy and complication rates.Open medicine (Warsaw, Poland) · 2024Article
- Identification of Promising Drug Candidates against Prostate Cancer through Computationally-Driven Drug Repurposing.International journal of molecular sciences · 2023Article
- Multiparametric MRI and Machine Learning Based Radiomic Models for Preoperative Prediction of Multiple Biological Characteristics in Prostate Cancer.Frontiers in oncology · 2022Article
- Can serum endoglin be used to improve the diagnostic performance in prostate cancer?World journal of urology · 2021Article
- Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management.Clinical proteomics · 2020Review
- Long-Term Clinical Outcomes of Radical Prostatectomy versus Watchful Waiting in Localized Prostate Cancer Patients: A Systematic Review and Meta-Analysis.Iranian journal of public health · 2019Review
- Evolution of Guidelines for Testosterone Replacement Therapy.Journal of clinical medicine · 2019Article
- Engaging African American Men as Citizen Scientists to Validate a Prostate Cancer Biomarker: Work-in-Progress.Progress in community health partnerships : research, education, and action · 2019Article
- Liquid Biopsy Potential Biomarkers in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2018Article
- Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera.Scientific reports · 2018Article
- The Clinical Efficacy of Prostate Cancer Screening in Worldwide and Iran: Narrative Review.World journal of oncology · 2018Review
- Association Analysis of a Microsatellite Repeat in theFrontiers in genetics · 2018Article
- Physicians' Perceptions of Factors Influencing the Treatment Decision-making Process for Men With Low-risk Prostate Cancer.Urology · 2017Article
- Prostate brachytherapy in Ghana: our initial experience.Journal of contemporary brachytherapy · 2016Article
- The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe study assessed the impact of prostate-specific antigen (PSA) testing in the United States by comparing the rates of PSA testing in U.S. counties to the rates of prostate biopsies and newly treated prostate cancer and to deaths from prostate cancer.
methodsWe examined the association between the percentage of men aged 66-74 from a nationally representative 5% Medicare sample who received PSA testing in each U.S. county in 1997 and the percent of men who received prostate biopsies or treatment for newly diagnosed prostate cancer in 1997 as well as mortality from prostate cancer and from all other causes from 1998 to 2007.
resultsAnalyses of 1,067 U.S. counties showed a significant relationship between the rate of PSA testing and both the rate of men undergoing treatment for prostate cancer and prostate cancer mortality (both p < .001) but no relationship with mortality from other causes. For every 100,000 men receiving a PSA test in 1997, an additional 4,894 men underwent prostate biopsy and 1,597 additional men underwent prostate cancer treatment in 1997, and 61 fewer men died from prostate cancer during 1998-2006. Analyses stratified by age and race produced similar results.
conclusionsPSA testing was associated with modest reductions in prostate cancer mortality and large increases in the number of men overdiagnosed with and overtreated for prostate cancer. The results are similar to those obtained by the large European randomized prospective trial of PSA testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.